The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
Pharmacodynamic effects in blood and tumor tissue of eftozanermin alfa, a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist.
 
Monica Motwani
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Dimple Modi
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Sudhir Penugonda
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Chun Zhang
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Joann Palma
No Relationships to Disclose
 
Alexis Cunningham
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - START
Stock and Other Ownership Interests - International Cancer Consultants; Oncoart Associated; START
Honoraria - HM Hospitales
Consulting or Advisory Role - Abbvie; Amcure; AstraZeneca; Celgene; EUSA Pharma; Gerson Lehrman Group; Guidepoint Global; Janssen-Cilag; Nanobiotix; Novartis; Pfizer; PsiOxus Therapeutics; Roche/Genentech; Seagen; SERVIER
Speakers' Bureau - Novartis
Research Funding - AstraZeneca; BeiGene; Novartis; START
Travel, Accommodations, Expenses - Roche/Genentech
Other Relationship - Investigational Therapeutics in Oncological Sciences
 
Maja J.A. de Jonge
Consulting or Advisory Role - Faron Pharmaceuticals
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; Agenus; Agios; Astellas Pharma; AstraZeneca; Black Diamond Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-MAB; Immunome; IQvia; Macrogenics; Pfizer; QED Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Shattuck Labs; Silverback Therapeutics; Sotio; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech